Precision Neuroscience has filed a notice of an exempt offering of securities to raise $249,999,984.00 in New Funding.

According to filings with the U.S. Securities and Exchange Commission, Precision Neuroscience is raising up to $249,999,984.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Precision Neuroscience
Precision Neuroscience develops brain-computer interfaces that create high-bandwidth digital connections with the brain without causing harm. Its current system is designed to help people with paralysis operate digital devices using only their thoughts, with the goal of restoring independence and connection for millions of people. The companys Layer 7 cortical interface has received FDA 510(k) clearance, has been used in clinical studies involving more than 100 patients, and is supported by more than 18 active hospital partners. Its technology has demonstrated control of computers and robotics and is designed to be removable and upgradeable without damaging the brain. Precision Neuroscience plans to expand the system to additional regions of the brain to enable new treatment and research possibilities, and its brain-computer interface is currently an investigational device not available for sale in the United States.

To learn more, visit https://www.precisionneuro.io/
LinkedIn: https://www.linkedin.com/company/precision-neuroscience-corporation/

Contact:
Michael Kaswan, Chief Financial Officer
https://www.linkedin.com/in/mikekaswan/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.